摘要 |
The present invention relates to a method for the prognosis of bone metastasis in renal cell carcinoma which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c- MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering renal cell carcinoma. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of renal cell carcinoma metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering renal cell carcinoma and for classifying a subject from renal cell carcinoma into a cohort. |